vs
Lemonade, Inc.（LMND）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Lemonade, Inc.的季度营收约是再鼎医药的1.8倍（$228.1M vs $127.1M），Lemonade, Inc.同比增速更快（53.3% vs 17.1%），Lemonade, Inc.自由现金流更多（$-25.9M vs $-26.7M），过去两年Lemonade, Inc.的营收复合增速更高（38.4% vs 20.8%）
Lemonade, Inc.是一家总部位于美国纽约的保险公司，在美国市场提供租客险、房屋险、车险、宠物险及定期寿险，在德国、荷兰推出财产及责任保险，法国市场提供租客险，当前拥有约290万用户，采用人工智能及聊天机器人替代人工处理理赔申请。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LMND vs ZLAB — 直观对比
营收规模更大
LMND
是对方的1.8倍
$127.1M
营收增速更快
LMND
高出36.2%
17.1%
自由现金流更多
LMND
多$799.0K
$-26.7M
两年增速更快
LMND
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $228.1M | $127.1M |
| 净利润 | $-21.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -9.0% | -54.6% |
| 净利率 | -9.5% | — |
| 营收同比 | 53.3% | 17.1% |
| 净利润同比 | 27.7% | — |
| 每股收益（稀释后） | $-0.27 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LMNDZLAB
| Q4 25 | $228.1M | $127.1M | ||
| Q3 25 | $194.5M | $115.4M | ||
| Q2 25 | $164.1M | $109.1M | ||
| Q1 25 | $151.2M | $105.7M | ||
| Q4 24 | $148.8M | $108.5M | ||
| Q3 24 | $136.6M | $101.8M | ||
| Q2 24 | $122.0M | $100.1M | ||
| Q1 24 | $119.1M | $87.1M |
净利润LMNDZLAB
| Q4 25 | $-21.7M | — | ||
| Q3 25 | $-37.5M | $-36.0M | ||
| Q2 25 | $-43.9M | $-40.7M | ||
| Q1 25 | $-62.4M | $-48.4M | ||
| Q4 24 | $-30.0M | — | ||
| Q3 24 | $-67.7M | $-41.7M | ||
| Q2 24 | $-57.2M | $-80.3M | ||
| Q1 24 | $-47.3M | $-53.5M |
毛利率LMNDZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率LMNDZLAB
| Q4 25 | -9.0% | -54.6% | ||
| Q3 25 | -18.7% | -42.3% | ||
| Q2 25 | -26.0% | -50.3% | ||
| Q1 25 | -40.6% | -53.3% | ||
| Q4 24 | -25.4% | -62.6% | ||
| Q3 24 | -48.2% | -66.6% | ||
| Q2 24 | -45.2% | -76.0% | ||
| Q1 24 | -38.0% | -80.7% |
净利率LMNDZLAB
| Q4 25 | -9.5% | — | ||
| Q3 25 | -19.3% | -31.2% | ||
| Q2 25 | -26.8% | -37.3% | ||
| Q1 25 | -41.3% | -45.8% | ||
| Q4 24 | -20.2% | — | ||
| Q3 24 | -49.6% | -40.9% | ||
| Q2 24 | -46.9% | -80.2% | ||
| Q1 24 | -39.7% | -61.4% |
每股收益（稀释后）LMNDZLAB
| Q4 25 | $-0.27 | $-0.05 | ||
| Q3 25 | $-0.51 | $-0.03 | ||
| Q2 25 | $-0.60 | $-0.04 | ||
| Q1 25 | $-0.86 | $-0.04 | ||
| Q4 24 | $-0.42 | $-0.09 | ||
| Q3 24 | $-0.95 | $-0.04 | ||
| Q2 24 | $-0.81 | $-0.08 | ||
| Q1 24 | $-0.67 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $399.1M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $533.6M | $715.5M |
| 总资产 | $1.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LMNDZLAB
| Q4 25 | $399.1M | $689.6M | ||
| Q3 25 | $369.4M | $717.2M | ||
| Q2 25 | $398.8M | $732.2M | ||
| Q1 25 | $329.7M | $757.3M | ||
| Q4 24 | $403.5M | $779.7M | ||
| Q3 24 | $360.9M | $616.1M | ||
| Q2 24 | $387.2M | $630.0M | ||
| Q1 24 | $300.8M | $650.8M |
股东权益LMNDZLAB
| Q4 25 | $533.6M | $715.5M | ||
| Q3 25 | $516.2M | $759.9M | ||
| Q2 25 | $527.1M | $791.7M | ||
| Q1 25 | $545.5M | $810.8M | ||
| Q4 24 | $593.4M | $840.9M | ||
| Q3 24 | $593.0M | $667.7M | ||
| Q2 24 | $635.2M | $704.2M | ||
| Q1 24 | $676.4M | $762.2M |
总资产LMNDZLAB
| Q4 25 | $1.9B | $1.2B | ||
| Q3 25 | $1.9B | $1.2B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $1.8B | $1.2B | ||
| Q3 24 | $1.8B | $985.3M | ||
| Q2 24 | $1.7B | $987.4M | ||
| Q1 24 | $1.6B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-25.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | -11.4% | -21.0% |
| 资本支出强度资本支出/营收 | 4.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-69.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LMNDZLAB
| Q4 25 | $-16.5M | $-26.0M | ||
| Q3 25 | $4.5M | $-32.0M | ||
| Q2 25 | $5.5M | $-31.0M | ||
| Q1 25 | $-47.2M | $-61.7M | ||
| Q4 24 | $-11.4M | $-55.8M | ||
| Q3 24 | $16.3M | $-26.8M | ||
| Q2 24 | $-11.7M | $-42.2M | ||
| Q1 24 | $-29.8M | $-90.1M |
自由现金流LMNDZLAB
| Q4 25 | $-25.9M | $-26.7M | ||
| Q3 25 | $2.6M | $-35.0M | ||
| Q2 25 | $3.4M | $-33.9M | ||
| Q1 25 | $-49.5M | $-63.2M | ||
| Q4 24 | $-20.8M | $-58.4M | ||
| Q3 24 | $14.1M | $-28.2M | ||
| Q2 24 | $-13.2M | $-42.9M | ||
| Q1 24 | $-32.3M | $-91.1M |
自由现金流率LMNDZLAB
| Q4 25 | -11.4% | -21.0% | ||
| Q3 25 | 1.3% | -30.4% | ||
| Q2 25 | 2.1% | -31.1% | ||
| Q1 25 | -32.7% | -59.9% | ||
| Q4 24 | -14.0% | -53.8% | ||
| Q3 24 | 10.3% | -27.7% | ||
| Q2 24 | -10.8% | -42.9% | ||
| Q1 24 | -27.1% | -104.5% |
资本支出强度LMNDZLAB
| Q4 25 | 4.1% | 0.5% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 1.5% | 1.5% | ||
| Q4 24 | 6.3% | 2.4% | ||
| Q3 24 | 1.6% | 1.3% | ||
| Q2 24 | 1.2% | 0.7% | ||
| Q1 24 | 2.1% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LMND
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
